AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:AZN
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: £66.17 billion
  • Outstanding Shares: 1,266,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 4,839.40
  • 200 Day Moving Avg: GBX 4,584.95
  • 52 Week Range: GBX 3,680 - GBX 5,505
  • Trailing P/E Ratio: 19.58
  • P/E Growth: 3.18
Sales & Book Value:
  • Annual Revenue: £22.29 billion
  • Price / Sales: 2.97
  • Book Value: GBX 10.26 per share
  • Price / Book: 5.09
  • Dividend Yield: 4.2%
  • EBIDTA: £5.84 billion
  • Average Volume: 2.33 million shs.

Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc declared a dividend on Thursday, February 2nd. Investors of record on Thursday, February 16th will be given a dividend of GBX 150.20 per share on Monday, March 20th. This represents a dividend yield of 3.52%. The ex-dividend date of this dividend is Thursday, February 16th. This is a positive change from AstraZeneca plc's previous dividend of $68.70. The official announcement can be viewed at this link. View AstraZeneca plc's Dividend History.

When will AstraZeneca plc make its next earnings announcement?

AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for AstraZeneca plc.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

21 equities research analysts have issued 12 month price objectives for AstraZeneca plc's shares. Their forecasts range from GBX 3,650 to GBX 6,500. On average, they anticipate AstraZeneca plc's share price to reach GBX 5,041.80 in the next twelve months. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of AstraZeneca plc stock cost?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 5,227.

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Ratings, 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: GBX 5,041.80

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
5/26/2017InvestecBoost Price TargetHoldGBX 4,600 -> GBX 5,000View Rating Details
5/26/2017Goldman Sachs Group IncSet Price TargetSellGBX 3,900View Rating Details
5/23/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 4,500View Rating Details
5/23/2017Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details
5/23/2017Shore CapitalReiterated RatingHoldView Rating Details
5/22/2017Deutsche Bank AGReiterated RatingBuyView Rating Details
5/20/2017Jefferies Group LLCSet Price TargetNeutralGBX 4,700View Rating Details
5/17/2017Berenberg BankBoost Price TargetBuyGBX 5,670 -> GBX 5,850View Rating Details
5/15/2017HSBC Holdings plcReiterated RatingReduceGBX 4,200View Rating Details
5/11/2017Barclays PLCReiterated RatingOverweightGBX 6,000View Rating Details
4/28/2017Sanford C. BernsteinSet Price TargetNeutralGBX 4,736View Rating Details
4/27/2017S&P GlobalSet Price TargetSellGBX 4,500View Rating Details
4/24/2017Morgan StanleyReiterated RatingBuyView Rating Details
4/21/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,000View Rating Details
4/19/2017Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details
4/3/2017BNP ParibasReiterated RatingNeutralGBX 5,300View Rating Details
4/3/2017Beaufort SecuritiesReiterated RatingHoldView Rating Details
3/23/2017Societe GeneraleReiterated RatingBuyView Rating Details
2/28/2017Bryan, Garnier & CoReiterated RatingBuyGBX 5,400View Rating Details
11/7/2016Citigroup IncReiterated RatingBuyView Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
(Data available from 5/28/2015 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.73 EPS


Dividend History by Quarter for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline logoAstraZeneca plc (AZN) Given a GBX 3,900 Price Target by Goldman Sachs Group Inc Analysts - May 26 at 11:02 PM logoAstraZeneca plc (AZN) PT Raised to GBX 5,000 at Investec - May 26 at 7:14 AM logoAstraZeneca Recalls One Lot Of BRILINTA 90mg Professional Sample Bottles - Nasdaq - May 25 at 9:42 PM logoAstraZeneca Sells Marketing Rights to Seloken in Europe - May 23 at 3:51 PM logoNovo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial - May 23 at 3:51 PM logoDeutsche Bank AG Reiterates "Buy" Rating for AstraZeneca plc (AZN) - May 22 at 7:00 PM logo[$$] AstraZeneca sells Seloken European rights for $300m - May 22 at 3:46 PM logoSevere asthma drug shows AstraZeneca promise beyond cancer - May 22 at 3:46 PM logoAstraZeneca, Recordati Enter Deal For Seloken; AstraZeneca To Receive $300 Mln - May 22 at 10:20 AM logoAstraZeneca plc (AZN) Given a GBX 4,700 Price Target at Jefferies Group LLC - May 21 at 4:20 PM logo[$$] Biotech Investor Clarus Ventures Raising $880 Million Fund - May 19 at 9:19 AM logoBerenberg Bank Increases AstraZeneca plc (AZN) Price Target to GBX 5,850 - May 19 at 12:08 AM logoAstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker - May 17 at 12:07 PM logoAstraZeneca Plc – Value Analysis (LONDON:AZN) : May 16, 2017 - May 16 at 3:52 PM logoAstraZeneca plc (AZN) Upgraded at Shore Capital - May 16 at 12:20 PM logoJPMorgan Chase & Co. Reiterates Neutral Rating for AstraZeneca plc (AZN) - May 14 at 12:08 PM logoJefferies Group LLC Lowers AstraZeneca plc (AZN) Price Target to GBX 4,700 - May 13 at 2:05 PM logoAstraZeneca, MedImmune Report Positive Results For Imfinzi Trial In NSCLC - May 12 at 9:20 PM logoAstraZeneca Group plc (AZN) - May 12 at 4:20 PM logoAstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next - May 12 at 4:20 PM logoFTSE 100 closes at an all-time high as AstraZeneca rallies, pound stalls - May 12 at 4:20 PM logoIs AstraZeneca The Next Big Player In Cancer Immunotherapies? - May 12 at 4:20 PM logoAstraZeneca Shares Jump On Cancer Trial That Rivals Dow's Merck - May 12 at 4:20 PM logoAstraZeneca's tralokinumab flunks late-stage asthma study - Seeking Alpha - May 10 at 11:57 PM logoShore Capital Reiterates "Sell" Rating for AstraZeneca plc (AZN) - May 10 at 12:33 PM logoAstraZeneca's New Drug: Too Little, Too Late? - Seeking Alpha - May 8 at 10:42 AM logoPharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit - May 8 at 10:42 AM logoAstraZeneca plc's (AZN) "Overweight" Rating Reaffirmed at Barclays PLC - May 7 at 8:55 PM logoAstraZeneca plc (AZN) Rating Reiterated by Shore Capital - May 7 at 4:02 PM logoAstraZeneca plc (AZN) Earns "Reduce" Rating from HSBC Holdings plc - May 6 at 10:34 PM logoAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts - May 3 at 10:06 AM logoAstraZeneca plc (AZN) Given Hold Rating at Jefferies Group LLC - April 30 at 7:58 PM logoAstraZeneca plc's (AZN) "Buy" Rating Reiterated at Liberum Capital - April 30 at 6:54 PM logo[$$] Pearson defends CEO pay ahead of investor showdown - April 30 at 5:04 PM logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital - April 30 at 3:47 PM logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by Investec - April 30 at 11:28 AM logoAstraZeneca plc (AZN) Given New GBX 5,350 Price Target at Deutsche Bank AG - April 30 at 9:56 AM logoAstraZeneca plc (AZN) Rating Reiterated by Barclays PLC - April 30 at 9:23 AM logoAstraZeneca plc (AZN) Price Target Cut to GBX 4,200 by Analysts at HSBC Holdings plc - April 30 at 9:22 AM logoJPMorgan Chase & Co. Increases AstraZeneca plc (AZN) Price Target to GBX 4,500 - April 30 at 6:22 AM logoAstraZeneca plc (AZN) Given a GBX 4,500 Price Target at S&P Global - April 28 at 8:56 PM logoAstraZeneca plc (AZN) Given a GBX 5,670 Price Target at Berenberg Bank - April 28 at 8:56 PM logoAstraZeneca plc's (AZN) Hold Rating Reaffirmed at Investec - April 28 at 8:54 PM logoAstraZeneca plc (AZN) Given "Sell" Rating at Shore Capital - April 28 at 8:54 PM logoAstraZeneca plc (AZN) Given Buy Rating at Liberum Capital - April 28 at 7:12 PM logoAstraZeneca plc's (AZN) "Hold" Rating Reaffirmed at Jefferies Group LLC - April 28 at 7:04 PM logoEdited Transcript of AZN.L earnings conference call or presentation 27-Apr-17 11:00am GMT - April 28 at 4:44 PM logoAstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates - April 28 at 4:44 PM logo[$$] Biotech and big pharma reap rewards from partnerships - April 28 at 4:44 PM logoSanford C. Bernstein Analysts Give AstraZeneca plc (AZN) a GBX 4,736 Price Target - April 28 at 6:38 AM


Social activity is not available for this stock.


AstraZeneca plc (AZN) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff